January 18, 2017

The Honorable Daniel Hawkins, Chairperson
House Committee on Health and Human Services
Statehouse, Room 521-E
Topeka, Kansas  66612

Dear Representative Hawkins:

SUBJECT:  Fiscal Note for HB 2029 by House Committee on Health and Human Services

In accordance with KSA 75-3715a, the following fiscal note concerning HB 2029 is respectfully submitted to your committee.

HB 2029 would schedule in the Kansas Uniform Controlled Substances Act any cannabidiol (cbd) investigational product approved by the U.S. Food and Drug Administration (FDA) as a prescription medication and scheduled under federal rule. The scheduling in Kansas would mirror the federal scheduling, which would allow legal access to the medication.

The passage of HB 2029 would have no fiscal effect for the Board of Pharmacy. Pharmacy inspectors would include these products as part of their standard review of pharmacies and their compliant practices. Adding such a substance to the Kansas Uniform Controlled Substances Act in schedules II, III, or IV, however, would require pharmacies to track and report dispensing of such substances to the Kansas Prescription Monitoring Program that is administered by the Board of Pharmacy. While pharmacies may have expenditures related to making changes to their electronic health records systems, it is not possible to estimate those costs. Any fiscal effect associated with HB 2029 is not reflected in The FY 2018 Governor’s Budget Report.

Sincerely,

Shawn Sullivan,
Director of the Budget

cc: Dan Thimmesch, Health & Environment
Alexandra Blasi, Board of Pharmacy